MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$362,258K
Net Income
$22,294K
Net Profit Margin
6.15%
EPS
$0.4
Unit: Thousand (K) dollars
Revenue Breakdown
Cardiopulmonary Segment-Operatin...
Neuromodulation Segment-Operatin...
Corporate Non Segment
Revenue Breakdown
US
Locations Excluding The United S...
Europe
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net revenue
362,258
360,921
357,753
352,524
Cost of sales
118,509
125,669
112,898
113,536
Gross profit
243,749
235,252
244,855
238,988
Selling, general, and administrative
143,568
138,844
138,522
137,780
Research and development
58,695
52,123
48,577
47,185
Impairment of long-lived assets
-
0
-
-
Other operating expense
-15
-1,707
-3,744
160
Operating income
41,471
42,578
54,012
54,183
Gain on debt extinguishment
-
1,326*
0
-2,651
Foreign exchange and other income/(expense)
-
-
-
-4,255
Snia environmental liability expense
0
1,738
1,745
1,677
Interest expense
8,291
10,857
10,863
12,280
Foreign exchange and other income/(expense)
-5,695
-3,674*
-7,493
-
Income (gain) before income tax
27,485
27,634
33,911
33,320
Income tax expense
4,340
-3,282
7,114
6,151
Loss from equity method investments
-851
-10
-13
-8
Net income (gain)
22,294
30,906
26,784
27,161
Basic EPS
0.41
0.566
0.49
0.5
Diluted EPS
0.4
0.573
0.49
0.5
Basic Average Shares
54,688,000
54,564,000
54,630,000
54,577,000
Diluted Average Shares
55,944,000
53,910,000
55,153,000
54,708,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Locations Excluding The
United States And...
$82,072K
(15.63%↑ Y/Y)
US
$69,279K
(13.88%↑ Y/Y)
Europe
$57,304K
(28.75%↑ Y/Y)
US
$115,400K
(6.52%↑ Y/Y)
Europe
$18,348K
(20.76%↑ Y/Y)
Locations Excluding The
United States And...
$18,040K
(17.41%↑ Y/Y)
Cardiopulmonary
Segment-Operating Segments
$208,655K
(18.34%↑ Y/Y)
Neuromodulation
Segment-Operating Segments
$151,788K
(9.28%↑ Y/Y)
Corporate Non Segment
$1,815K
(10.54%↑ Y/Y)
Net revenue
$362,258K
(14.33%↑ Y/Y)
Gross profit
$243,749K
(10.41%↑ Y/Y)
Cost of sales
$118,509K
(23.34%↑ Y/Y)
Operating income
$41,471K
(-14.70%↓ Y/Y)
Selling, general, and
administrative
$143,568K
(7.41%↑ Y/Y)
Research and development
$58,695K
(54.95%↑ Y/Y)
Other operating
expense
-$15K
(97.55%↑ Y/Y)
Income (gain) before
income tax
$27,485K
(108.71%↑ Y/Y)
Interest expense
$8,291K
(-45.76%↓ Y/Y)
Foreign exchange and
other...
-$5,695K
(-149.89%↓ Y/Y)
Net income (gain)
$22,294K
(106.81%↑ Y/Y)
Income tax expense
$4,340K
(-62.77%↓ Y/Y)
Loss from equity
method investments
-$851K
(-4155.00%↓ Y/Y)
Buy us a coffee
LivaNova PLC (LIVN)
LivaNova PLC (LIVN)